Pharmaceutical Companies in Qatar
A comprehensive guide to the pharmaceutical industry in Qatar — the highest healthcare spending per capita in MENA. Covering major pharma companies, MOPH regulatory framework, Qatar National Vision 2030, market data, distribution channels (Hamad Medical Corp, Sidra Medicine), and strategic opportunities.
Last updated: February 2026 · Sources: MOPH, BioNixus MEA, QPI, Sidra Medicine, company filings
Cite this guide
BioNixus. "Pharmaceutical Companies in Qatar: Complete Industry Guide 2026." BioNixus Healthcare Market Research, Feb. 2026, https://www.bionixus.com/pharmaceutical-companies-qatar.
Licensed under CC BY 4.0 — free to share and adapt with attribution.
$0.9B
Pharmaceutical market value
12.3%
Year-over-year growth
2.7M
Population
$333
Pharma spending per capita
Qatar Pharmaceutical Market Overview
Qatar's pharmaceutical market has the highest healthcare spending per capita in MENA, with pharma spending at $333 per capita and a total market valued at approximately US$0.9 billion. With a population of 2.7 million, the market is growing at 12.3% year-over-year — one of the fastest growth rates in the region — driven by Qatar National Vision 2030, post-FIFA infrastructure, clinical research expansion (Sidra Medicine CAR-T and specialty therapies), and rising demand for biologics and specialty medicines.
Approximately 95% of pharmaceuticals are imported, though local manufacturing is expanding. Qatar Pharmaceutical Industries (QPI) is planning 140 drugs and a new plant by 2028; QLife Pharma is WHO cGMP certified. Sidra Medicine is a key centre for specialty and advanced therapies. The market is regulated by the Ministry of Public Health (MOPH), Pharmacy & Drug Control.
Pricing follows reference pricing (KSA, UAE, select EU). Registration typically takes 8–16 months with 5-year renewal. For a broader regional comparison, see our MENA Pharmaceutical Market Data 2026 and GCC Pharmaceutical Market Access Guide.
Top Pharmaceutical Companies in Qatar
The following table lists the major pharmaceutical companies operating in Qatar — including local manufacturers, multinational corporation offices, regional players, and leading pharmacy chains and distributors.
| Company | HQ |
|---|---|
| Qatar Pharmaceutical Industries (QPI) | Qatar |
| QLife Pharma | Qatar |
| Pfizer | USA |
| Novartis | Switzerland |
| Roche | Switzerland |
| Sanofi | France |
| AstraZeneca | UK / Sweden |
| GSK (GlaxoSmithKline) | UK |
| MSD (Merck & Co.) | USA |
| Novo Nordisk | Denmark |
| AbbVie | USA |
| Boehringer Ingelheim | Germany |
| Julphar | UAE |
| Hikma Pharmaceuticals | Jordan / UK |
| Doha Pharmacy | Qatar |
| Al Emadi Hospital Pharmacy | Qatar |
| National Health Care Group | Qatar |
| Qatar Pharmacy | Qatar |
List of Pharmaceutical Companies in Qatar by Category
Qatar pharmaceutical companies span local manufacturers (QPI, QLife Pharma), multinational offices, regional players, and distributors serving Hamad Medical Corp and the growing private sector.
Local Manufacturers
Qatar has two local pharmaceutical manufacturers: QPI (planning 140 drugs, new plant 2028) and QLife Pharma (WHO cGMP, wound healing/cardiovascular). Qatar National Vision 2030 supports local production to reduce import dependency (~95%).
- ✓ Qatar Pharmaceutical Industries (QPI)
- ✓ QLife Pharma
Multinational Pharma Offices
Major global pharmaceutical companies maintain offices in Qatar. MNCs dominate the innovator and specialty segment; Roche has a Sidra Medicine partnership. Qatar is an important high-value market per capita.
- ✓ Pfizer
- ✓ Novartis
- ✓ Roche
- ✓ Sanofi
- ✓ AstraZeneca
- ✓ GSK (GlaxoSmithKline)
- ✓ MSD (Merck & Co.)
- ✓ Novo Nordisk
- ✓ AbbVie
- ✓ Boehringer Ingelheim
Regional Pharma Companies
Regional players Julphar and Hikma Pharmaceuticals supply generics and injectables to Qatar, benefiting from GCC regulatory alignment.
- ✓ Julphar
- ✓ Hikma Pharmaceuticals
Pharmacy Chains & Distributors
Doha Pharmacy, Al Emadi Hospital Pharmacy, National Health Care Group, and Qatar Pharmacy serve retail and hospital channels; retail pharmacies are expanding.
- ✓ Doha Pharmacy
- ✓ Al Emadi Hospital Pharmacy
- ✓ National Health Care Group
- ✓ Qatar Pharmacy
Pharma Companies in Qatar: MOPH Regulatory Landscape
The Ministry of Public Health (MOPH), Pharmacy & Drug Control Department oversees all pharmaceutical registration, quality control, pricing, and pharmacovigilance in Qatar.
Regulatory Authority
The Ministry of Public Health (MOPH), Pharmacy & Drug Control oversees pharmaceutical registration, quality, pricing, and import licensing. Submissions follow CTD format.
Registration Timeline
8–16 months
Renewal Period
5 years
Pricing Model
Reference pricing (KSA, UAE, select EU)
Key Registration Requirements
- ✓CTD-format dossier via MOPH process
- ✓GMP certificates from recognised authorities
- ✓Stability data for relevant climate zone
- ✓Arabic labelling mandatory on all products
- ✓Clinical trial / bioequivalence data as applicable
- ✓Certificate of Pharmaceutical Product (CPP)
- Local authorised representative mandatory
Qatar National Vision 2030 & Local Manufacturing
Qatar National Vision 2030 supports local pharmaceutical production. QPI is expanding with a new plant (2028) and 140-drug pipeline; QLife Pharma is WHO cGMP certified. For complete GCC registration details, see our GCC Pharmaceutical Market Access Guide.
Drug Distribution Channels in Qatar
Qatar's pharmaceutical distribution is led by the government channel (Hamad Medical Corp) with a growing private sector and expanding retail pharmacies.
Government Channel
Hamad Medical Corporation (HMC) dominates the government sector and is the largest public healthcare provider. Government procurement drives a significant share of pharmaceutical spend.
- ► Hamad Medical Corp (HMC) — main public provider
- ► Tender and formulary-based procurement
- ► Sidra Medicine — specialty and advanced therapies
Private Sector & Retail
The private sector is growing. Al Emadi and Al Ahli hospitals are key private players. Retail pharmacies (Doha Pharmacy, Qatar Pharmacy, National Health Care Group) are expanding; e-pharmacy and digital health are emerging.
- ► Al Emadi Hospital, Al Ahli Hospital
- ► Doha Pharmacy, Qatar Pharmacy, National Health Care Group
- ► E-pharmacy and digital health growth
Qatar Pharmaceutical Market Growth Drivers
Qatar National Vision 2030, post-FIFA infrastructure, and clinical research expansion are driving strong growth in Qatar's pharmaceutical sector.
Qatar National Vision 2030
National plan supports healthcare excellence, local pharmaceutical manufacturing (QPI 2028 plant, QLife Pharma), and reduced import dependency. Healthcare and pharma are strategic priorities.
Clinical Research Expansion
Sidra Medicine drives specialty and advanced therapies including CAR-T. Qatar is building a reputation for clinical research and high-end care, attracting MNC partnerships (e.g. Roche).
Post-FIFA Infrastructure
Post-2022 FIFA World Cup infrastructure and healthcare investments continue to support hospital capacity, formulary expansion, and pharmaceutical utilisation.
E-Pharmacy & Digital Health
E-pharmacy and digital health initiatives are expanding access and convenience, supporting growth in retail and chronic disease management.
Biologics & Specialty Medicines
Demand for biologics and specialty medicines is rising, supported by Sidra Medicine and high per-capita spending ($333 pharma/capita — highest in MENA).
Local Manufacturing (QPI 2028)
Qatar Pharmaceutical Industries' new plant (2028) and 140-drug pipeline will increase local supply and create opportunities for partnerships and supply chain diversification.
How BioNixus Supports Pharma Companies in Qatar
BioNixus is a leading healthcare market research company with expertise in the Qatar and GCC pharmaceutical markets. We help pharma, biotech, and medtech companies with:
Physician Surveys & KOL Mapping
Quantitative and qualitative research with Qatar physicians across Hamad Medical Corp, Sidra Medicine, and private hospitals. Arabic-English bilingual capabilities.
Market Access & MOPH Strategy
MOPH formulary strategy, reference pricing analysis, reimbursement landscape, and payer research to optimise commercial success in Qatar.
Competitive Intelligence
Monitoring of competitor launches, tender outcomes, formulary changes, and market share across therapeutic areas in Qatar and the GCC.
Market Entry Strategy
Market assessment including MOPH regulatory pathway, local partner identification, KOL engagement, and go-to-market planning for Qatar.
Frequently Asked Questions
How many pharmaceutical companies operate in Qatar?
Qatar has approximately 18 major pharmaceutical companies operating in the market — including local manufacturers (QPI, QLife Pharma), multinational offices (Pfizer, Novartis, Roche, Sanofi, AstraZeneca, GSK, MSD, Novo Nordisk, AbbVie, Boehringer Ingelheim), regional players (Julphar, Hikma), and distributors (Doha Pharmacy, Al Emadi Hospital Pharmacy, National Health Care Group, Qatar Pharmacy). The market is valued at $0.9 billion with 12.3% growth and the highest pharma spending per capita in MENA ($333).
What is the size of Qatar's pharmaceutical market?
Qatar's pharmaceutical market is valued at approximately US$0.9 billion, with a population of 2.7 million and pharma spending per capita of $333 — the highest in the MENA region. The market is growing at 12.3% year-over-year, driven by Qatar National Vision 2030, post-FIFA infrastructure, clinical research expansion (e.g. Sidra Medicine CAR-T), and growing demand for biologics and specialty medicines. About 95% of pharmaceuticals are imported.
How do you register a pharmaceutical product with MOPH Qatar?
Drug registration with the Ministry of Public Health (MOPH), Pharmacy & Drug Control Department requires submission of a Common Technical Document (CTD). The process typically takes 8–16 months and requires a local authorised representative, GMP certificates, stability data, Arabic labelling, and clinical/bioequivalence data as applicable. Registration is valid for 5 years before renewal.
Who dominates pharmaceutical distribution in Qatar?
Hamad Medical Corporation (HMC) dominates the government channel and is the largest public healthcare provider. The private sector is growing, with Al Emadi and Al Ahli hospitals among key private players. Retail pharmacies (e.g. Doha Pharmacy, Qatar Pharmacy) are expanding. E-pharmacy and digital health are emerging. Pricing follows reference pricing (KSA, UAE, select EU).
Is local pharmaceutical manufacturing growing in Qatar?
Yes. Qatar has two local manufacturers — Qatar Pharmaceutical Industries (QPI) and QLife Pharma (WHO cGMP). QPI is planning 140 drugs and a new plant by 2028 under Qatar National Vision 2030. Local manufacturing is encouraged to reduce import dependency (currently ~95%). Sidra Medicine supports clinical research and specialty therapies including CAR-T.
Do I need a local partner to sell pharmaceuticals in Qatar?
Yes. Foreign pharmaceutical companies must appoint a local authorised representative to handle MOPH regulatory submissions, in-country logistics, and pharmacovigilance. This is a legal requirement for all foreign manufacturers selling in Qatar.
Data Sources & Methodology
This guide aggregates publicly available information from:
- BioNixus Middle East & Africa Pharmaceutical Market Report
- MOPH — Pharmacy & Drug Control
- Qatar Pharmaceutical Industries (QPI), QLife Pharma
- Sidra Medicine, Hamad Medical Corporation
- BioNixus proprietary research (2024–2025)
For customised market intelligence on Qatar, contact our team.
Need Market Intelligence on Qatar?
BioNixus delivers custom pharmaceutical market research across Qatar and the GCC — physician surveys, competitive intelligence, market access strategy, and KOL mapping.